OncoMatch/Clinical Trials/NCT04186585
Recommended Dose Estimation of BP-C2
Is NCT04186585 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies BP-C2 for prostate cancer.
Treatment: BP-C2 — The aim is to estimate an oral administered recommended dose of BP-C2 in addition to hormone treatment of prostate cancer. The study population consists of prostatic cancer patients between 18 and 80 years of age undergoing hormonal treatment. Four patients will be recruited consecutively from each of two participating hospital. The study will be performed as an open, one-dimensional multi-center trial with a 3-level within-patient Response Surface Pathway (RSP) design.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Prior therapy
Must have received: hormonal therapy
under hormonal treatment
Lab requirements
Kidney function
serum creatinine ≤120 µmol/l
Liver function
total bilirubin ≤34 µmol/l and ALAT ≤3x ULN (≤5x ULN if liver metastases)
Cardiac function
No clinically significant abnormal ECG
Abnormal liver function classified as total bilirubin >34 µmol/l or ALAT > 3 times the upper normal range (ULN). In case of metastases in the liver, the ALAT limit for exclusion is set to 5 x ULN. Abnormal kidney function defined by serum creatinine >120 µmol/l. Clinically significant abnormal ECG.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify